BioMimetic Therapeutics, Inc. to Report 2011 Second Quarter Financial Results on August 4
FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three months ended June 30, 2011, on Thursday, August 4, 2011 after the close of market. The Company will host a conference call and audio webcast to discuss its second quarter financial results, product development programs and business activities on Friday, August 5 at 8:30 a.m. EDT.
The conference call may be accessed on August 5, 2011 by dialing (877) 224 - 4059 (passcode: 87363322) for the U.S. and Canada. The international dial in number is (706) 902 - 2069, and the same passcode applies. Participants should dial in 10 minutes prior to the call.
A live webcast of the conference call will be available on the Investor Relations section of BioMimetic’s website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.
About BioMimetic Therapeutics
BioMimetic Therapeutics (NASDAQ: BMTI) specializes in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics and sports medicine applications. All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.
In May 2011, the United States FDA Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee voted favorably on the safety, efficacy and risk profile for the use of Augment® Bone Graft as an alternative to autograft in hindfoot and ankle fusions.
In November 2009, BioMimetic received regulatory approval to begin marketing Augment Bone Graft as an alternative to autograft in foot and ankle fusion indications in Canada.
In 2005, BioMimetic received marketing approval from the FDA for GEM 21S® (rhPDGF-BB/β-TCP), a grafting material for bone and periodontal regeneration.
In addition to Augment Bone Graft, the Company is currently sponsoring clinical trials with Augment® Injectable Bone Graft for the treatment of hindfoot fusions and Augment® Rotator Cuff Graft for the surgical treatment of rotator cuff tears.
GEM 21S is a trademark of Luitpold Pharmaceuticals, Inc., who markets this product through its Osteohealth division in the United States and Canada.
For further information contact Kearstin Patterson, director of corporate communications, at 615-236-4419.